A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.

Autor: Alexis, Andrew F.¹ (AUTHOR) drandrewalexis@gmail.com, Gooderham, Melinda² (AUTHOR), Kwatra, Shawn G.³ (AUTHOR), Amin, Ahmad⁴ (AUTHOR), Taylor, Susan⁵ (AUTHOR), Espaillat, Ramon⁶ (AUTHOR), Rettig, Trisha⁶ (AUTHOR), Wu, Tianshuang⁶ (AUTHOR), Shi, Linyu⁶ (AUTHOR), Kaldas, Mark I.⁶ (AUTHOR), Dilley, Deanne M.⁶ (AUTHOR), Sinvhal, Ranjeeta⁶ (AUTHOR), Nduaka, Chudy⁶ (AUTHOR), Lockshin, Benjamin⁷ (AUTHOR)

Publikováno v: Dermatology & Therapy. Oct2024, Vol. 14 Issue 10, p2877-2887. 11p.

Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials

Autor: Lynde, Charles, Guenther, Lyn, Sauder, Maxwell, Bissonnette, Robert, Rao, Jaggi, Day, Isaiah, Devani, Alim, Metelitsa, Andrei, Grewal, Parbeer, Molin, Sonja, Ruer-Mulard, Mireille, Giordano-Labadie, Françoise, Maillard, Hervé, Reguiai, Ziad, Bernier, Claire, Leleu, Camille, Seneschal, Julien, Staumont-Sallé, Delphine, Hubiche, Thomas, Jacobzone, Caroline, Khemis, Abdallah, Crépy, Marie-Noëlle, Worm, Margitta, Bauer, Andrea, Sell, Sabine, Ekanayake-Bohlig, Swarna, Pauser, Sylvia, Buhl, Timo, Schwinn, Andreas, Eberlein, Bernadette, Quist, Sven, Bauer, Boris, Peris, Ketty, Rossi, Maria Teresa, Fargnoli, Maria, Naldi, Luigi, Stingeni, Luca, Ferrucci, Silvia, Walecka-Herniczek, Irena, Krasowska, Dorota, Lesiak, Aleksandra, Okuniewska, Aleksandra, Pulka, Grażyna, Dyczek, Malgorzata, Kwiek, Bartlomiej, Czajkowski, Rafal, Myśliwiec, Hanna, Mohandas, Padma, Cliff, Sandeep, Warren, Richard, Cousen, Pippa, Johnston, Graham, Woolf, Richard, Papp, Kim, Adam, David, Toth, Darryl, Hong, Chih-ho, Turchin, Irina, Niakosari, Firouzeh, Poulos, Elena, Rivers, Jason, Ohayon, Jason, Gooderham, Melinda, Tjioe, Milan, Rustemeyer, Thomas, de Bruin-Weller, Marjolein S., Schuttelaar, Marie L.A., Molhoek, Judith, Oosting, Bert, Pinter, Andreas, Kaspari, Markus, Magnolo, Nina, Sebastian, Michael, Thaci, Diamant, Schliemann, Sibylle, Radny, Peter, Leitz, Nicolas, Tsianakas, Athanasios, Yazdi, Amir, Kamstrup, Maria, Sommerlund, Mette, Zachariae, Claus, Owczarek, Witold, Dudra-Jastrzebska, Monika, Reich, Adam, Kowalska-Oledzka, Elzbieta, Szepietowski, Jacek, Poznanska, Maria, Weglowska, Jolanta, Aerts, Olivier, Roquet-Gravy, Pierre-Paul, Lanssens, Sven, Castelijns, Francisca, Scheers, Christelle, Suys, Erwin, Kint, Bernard, Serra-Baldrich, Esther, Carrascosa, José Manuel, de la Cueva Dobao, Pablo, Izu, Rosa, Silvestre, Juan Francisco, Coto-Segura, Pablo, Fernández-Orland, Almudena, Warren, Richard B, Agner, Tove, Schuttelaar, Marie L A, Baranowski, Keith, Korn, Sofie, Kurvits, Merle, Plohberger, Ursula, Strange Vest, Natacha

Publikováno v: In The Lancet 3-9 August 2024 404(10451):461-473

Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial

Autor: Stein Gold, Linda, Adam, David N., Albrecht, Lorne, Alonso-Llamazares, Javier, Ferris, Laura K., Gooderham, Melinda J., Hong, H. Chih-ho, Kempers, Steven E., Kircik, Leon H., Lebwohl, Mark, Loo, Wei Jing, Nahm, Walter K., Papp, Kim A., Stewart, Daniel, Toth, Darryl P., Zirwas, Matthew, Krupa, David, Snyder, Scott, Burnett, Patrick, Higham, Robert, Berk, David R.

Publikováno v: In Journal of the American Academy of Dermatology August 2024 91(2):273-280

Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)

Autor: Warren, Richard B., French, Lars E., Blauvelt, Andrew, Langley, Richard G., Egeberg, Alexander, Mrowietz, Ulrich, Hunter, Hamish J.A., Gooderham, Melinda, Soerensen, Per, Andres, Philippe, Sommer, Morten O.A., Carlsson, Anna, Kjøller, Kim D., Strober, Bruce E.

Publikováno v: In Journal of the American Academy of Dermatology March 2024 90(3):494-503

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.